In another major M&A deal, Amgen announced plans to purchase around 20 percent of Chinese company BeiGene for $2.7 billion in cash as it works to commercialize its latest oncology products in China. The acquisition represents a purchase price of $174.85 per share of BeiGene, a 26 percent premium over the company’s Oct. 31 closing…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
